ArticleJournal of the Egyptian National Cancer Institute2026
Modulated calcium-sensing receptor (CaSR) expression in human breast cancer provided insights into tumor progression and therapeutic potential.
Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The calcium-sensing receptor (CaSR) plays a crucial role in cellular signaling and has been implicated in cancer progression. However, its specific role in breast cancer remains unclear. This study aimed to investigate CaSR gene expression levels, its correlation with oncogenic pathways, and its protein localization in human breast cancer tissues.Quantitative real-time PCR (qRT-PCR) was used to analyze the relative expression of CaSR and associated genes in malignant and adjacent non-malignant breast cancer tissue samples. Pearson correlation analysis was performed to assess relationships between CaSR and other oncogenic markers. Immunohistochemistry (IHC) was conducted to evaluate CaSR protein localization and intensity in different breast cancer grades and fibroadenoma tissues.Our findings revealed that 56% of patients exhibited elevated CaSR expression, with significant positive correlations between CaSR and oncogenic genes such as HOTAIR, SNOR78, BC200, DSG1, DSC1, HER2, BRCA1, p38 MAPK, and Akt (p = 0.001 for most correlations). Additionally, CaSR expression negatively correlated with menopausal status (p = 0.001), suggesting hormonal influences on its regulation. IHC analysis showed strong membranous and cytoplasmic staining in grade II tumors without metastasis (+ 3) but weak or undetectable CaSR expression in advanced metastatic cases. These findings indicate a potential role for CaSR in tumor progression, adhesion, and metastasis.Importantly, this study provides novel evidence linking CaSR expression to non-coding RNAs, desmosomal adhesion molecules, and MAPK/AKT signaling pathways, highlighting previously unexplored mechanisms through which CaSR may influence breast cancer progression and metastatic behavior. Further research is needed to determine its potential as a biomarker or therapeutic target in breast cancer treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.